Resources

PEG-Free Shielding Lipids

 Explore how PEG‑free shielding lipids enhance LNP stability, circulation, and targeting while overcoming PEG‑related limitations to enable more flexible and effective RNA delivery. 

Shielding lipids are essential components in lipid nanoparticle (LNP) formulations, playing a key role in stability, circulation time, biodistribution, and delivery efficiency. As concerns around PEGylation continue to grow, next-generation PEG-free alternatives are emerging to support safer, more effective, and more versatile nucleic acid delivery systems.

This product highlight explores innovative shielding strategies designed to maintain the benefits of steric stabilization while improving formulation flexibility, in vivo performance, and compatibility with advanced RNA therapeutics and gene delivery applications.


Form

Download the PEG-Free Shielding Lipids Product Highlight

PEG- Free Shielding Lipids 2026

Access the full highlight to discover our next‑generation PEG‑free shielding lipid technology that improve formulation flexibility, in vivo performance, and compatibility with advanced RNA therapeutics. 

You will learn:

 The Role of Shielding Lipids in Advanced LNP Design 

 Supporting stability, circulation, and formulation performance 

Shielding lipids are fundamental components in lipid nanoparticle formulations, helping create a protective interface between the LNP and the biological environment. Their properties strongly influence nanoparticle stability, immune interactions, and delivery efficiency. Key functionalities of shielding lipids include:

  • Minimizing protein adsorption and immune recognition
  • Improving stability during formulation and storage
  • Extending circulation time in vivo
  • Supporting reproducible nanoparticle assembly and encapsulation
  • Enhancing biodistribution and delivery performance

Careful selection of shielding systems is essential for developing scalable and high-performing LNP formulations for RNA therapeutics and gene delivery applications. 

The PEG Dilemma 

Addressing the limitations of PEGylation 

Although PEGylated lipids have long been considered the gold standard for LNP stabilization, increasing evidence points to challenges including anti-PEG antibodies, accelerated blood clearance, immunogenicity concerns, and reduced cellular uptake during repeated dosing strategies. 

PEG-Free Shielding Lipids for Advanced Therapies 

Next-generation alternatives for RNA delivery 

Curapath’s PEG-free shielding lipid portfolio is designed to maintain steric stabilization while improving formulation flexibility and in vivo performance. These technologies support enhanced stability, prolonged circulation, lyophilization compatibility, and optimized biodistribution for gene therapies and RNA vaccines. 

Enabling Active Targeting in LNP Development  

By combining PEG-free shielding lipids with conjugation technologies such as CliCr®, LNPs can be functionalized with targeting ligands including peptides and antibodies. This approach enables increased tissue selectivity, improved safety profiles, and customizable delivery strategies for hard-to-reach targets such as T-cells, lung, and CNS tissues. 

Related Resources

Explore additional Curapath resources covering advanced drug delivery systems, analytical characterization, and nanoparticle development.

 Discover technical insights, application notes, and scientific content designed to support RNA therapeutics, lipid nanoparticles, and polymer-based delivery platforms. 

PEG Alternatives:

PEG Alternatives: Polymers Reshaping Lipid Nanoparticle Drug Delivery

Replacing PEG in lipid nanoparticles (LNPs) marks a critical evolution in the development of safer and more effective nucleic acid delivery systems. While PEG has long been the gold standard for nanoparticle stabilization, its association with immunogenicity and reduced efficacy upon repeat dosing has sparked a growing shift toward alternative polymers. Emerging materials like polysarcosine and poly(2-oxazoline)s offer comparable stealth and formulation performance, without triggering unwanted immune responses, paving the way for next-generation RNA therapeutics and gene delivery platforms. 

Diseño sin título (6)
Products

Curapath Product Catalog

Discover Curapath's cutting-edge offerings in our catalog. Explore our LNP and PNP components, as well as our polymer conjugates, all designed to advance drug delivery. Enhance your research and development with our high-quality products. 

para el siguiente post del blog
Formulation Screening

Formulation Development Services

 Discover Curapath’s Essential, Advanced, and Expert formulation packages for LNP & PNP systems, flexible, cost-effective solutions for drug delivery development. 

primer post
Next generation LNP Development

Next generation LNP Development

Certest and Curapath have joined forces to develop a novel LNP formulation leveraging the complementary Benefits of their proprietary excipients

Captura de pantalla 2025-03-17 133515
CDMO

CDMO Services Brochure

This leaflet outlines Curapath’s lipid- and polymer-based CDMO platform for advanced drug delivery, covering drug substance and drug product development, analytical services, GMP manufacturing, and sterile Fill & Finish capabilities.

 

 

segundo
PEG‑Free Shielding Lipids

Frequently asked Questions

Curapath is a European Contract Development and Manufacturing Organization (CDMO) specialized in lipid- and polymer-based delivery systems. We support biotech and pharmaceutical companies from early development through GMP-ready manufacturing.


Our core expertise includes polymer and lipid excipients, lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), polymer–drug conjugates, and coating polymers.

PEG-free shielding lipids are next-generation stabilizing lipids designed to replace traditional PEGylated lipids in lipid nanoparticle (LNP) formulations. These excipients create a hydrophilic protective layer around LNPs, helping to improve nanoparticle stability, circulation time, and overall formulation performance while avoiding the limitations commonly associated with PEG.

Unlike conventional PEG-lipids, PEG-free alternatives — such as polysarcosine (PSar)-based or other polymer-based shielding lipids — are being developed to support enhanced biocompatibility, reduced immunogenicity concerns, and improved repeat dosing potential. They can also contribute to better particle integrity during manufacturing, storage, and lyophilization processes.

PEG-free shielding lipids are increasingly explored in advanced RNA and gene delivery applications, including mRNA, saRNA, siRNA, CRISPR, and targeted LNP systems, particularly where long circulation times, extrahepatic delivery, or repeated administration are important considerations.

 

PEGylated lipids have traditionally been used in lipid nanoparticle (LNP) formulations to improve stability, reduce aggregation, and prolong circulation time. However, growing evidence suggests that PEG can also introduce several limitations that may impact the safety and performance of advanced drug delivery systems.

One of the main concerns is the development of anti-PEG antibodies, which can lead to accelerated blood clearance (ABC) upon repeated administration. This immune recognition may reduce LNP circulation time, decrease therapeutic efficacy, and limit the potential for chronic or repeat-dose treatments. In some cases, PEG has also been associated with hypersensitivity reactions and complement activation.

As RNA therapeutics and gene delivery applications continue to evolve, there is increasing interest in PEG-free alternatives that can maintain or improve nanoparticle stability while reducing immunogenicity risks. Next-generation shielding lipids — including polysarcosine (PSar)-based and other polymer-based systems — are being explored to support repeat dosing strategies, enhanced biocompatibility, improved extrahepatic delivery, and more robust formulation performance.

Replacing PEG may also provide advantages in formulation flexibility, targeting strategies, and long-term manufacturability for next-generation LNP therapeutics.

 

Yes. PEG-free shielding lipids can be engineered to support active targeting strategies while maintaining nanoparticle stability and performance. By incorporating functional groups compatible with ligand conjugation, these shielding systems can enable the attachment of antibodies, peptides, or other targeting moieties to guide LNPs toward specific tissues or cell types.

Compared to traditional PEGylated systems, PEG-free approaches based on materials such as polysarcosine (PSar) or polyamino acid-derived shielding lipids may help reduce some of the limitations associated with PEG, including accelerated blood clearance and potential immunogenicity concerns. This makes them attractive for applications requiring repeat dosing or extrahepatic delivery.

In addition, PEG-free shielding lipids can be designed to preserve particle integrity, colloidal stability, and manufacturability while enabling more advanced targeted delivery strategies for next-generation RNA and gene therapie

 

 PEG-free shielding lipids can enhance colloidal stability, support improved particle integrity, and enable more flexible formulation design. Depending on the system, they may also contribute to better repeat dosing compatibility, reduced immunogenicity concerns, and improved delivery performance for advanced RNA therapeutics. 

You can discuss a project with Curapath by leaving a message here or reaching out to bd@curapath.com

Contact
Lipid-Nanopeptide_0
Support for Your Therapeutic Program

Contact a Chemist Today

Contact Us, and we can discuss your specific therapeutic program and how Curapath can help build the right solution to advance your unique drug.